Novartis AG

Open: 100.98 Close: 101.03 Change: 0.05

Our AI found 7 flaws in Novartis AG.

Are looking for the most relevant information about Novartis AG? Investor spend a lot of time searching for information to make investment decisions in Novartis AG. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Novartis AG are: Novartis, company, AG, pharmaceutical, price, acquire, still, and the most common words in the summary are: novartis, company, ag, job, market, bloomberg, pharmaceutical, . One of the sentences in the summary was: The overall consensus recommendation for shares in the company is Buy. …

Concept Map

Semantic Network

Stock Summary

Novartis AG researches, develops, manufactures, markets, markets healthcare products. The company operates through two segments: Innovative Medicines and Sandoz. Novarti has a license and collaboration agreement with Alnylam Pharmaceuticals.

Today's Summary

Novartis AG to acquire MorphoSys AG for $73-per-share, for a total of $2.9 billion. The overall consensus recommendation for shares in the company is Buy. Share price has outperformed the FTSE Global All Cap Index.

Today's News

Novartis AG (NOVN.SW) stock price, news, quote & history - yahoo finance.sw) Stock Price, News, Quote & History. Novartis AG to acquire MorphoSys AG for $73-per-share, for a total of $2.9 billion. The deal is still subject to closing conditions, which are still under closing conditions. Novartis AG is a Switzerland-based pharmaceutical company. The overall consensus recommendation for shares in the company is Buy. Share price has outperformed the FTSE Global All Cap Index by +14. Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel. The pharmaceutical and agrochemical divisions of both companies formed Novaris as an independent entity. The company divested its agrochemicals and genetically modified crops business in 2000. Novartis agreed to pay $678 million to settle allegations that the company violated the False Claims Act and Anti-Kickback Statute by paying physicians to induce them to prescribe certain of the companys drugs. In March 2018, GlaxoSmithKline announced that it has reached an agreement with Novaris to acquire Novartes 36.5 percent stake in their Consumer Healthcare Joint Venture. Federal prosecutors filed two lawsuits against Novartis under the False Claims Act for off-label marketing and kickbacks; in both suits, prosecutors are seeking treble damages. Outside the US, Novartes markets the drug ranibizumab (trade name Lucentis) outside the US.

Stock Profile

"Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland."

Keywords

This document will help you to evaluate Novartis AG without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Novartis AG are: Novartis, company, AG, pharmaceutical, price, acquire, still, and the most common words in the summary are: novartis, company, ag, job, market, bloomberg, pharmaceutical, . One of the sentences in the summary was: The overall consensus recommendation for shares in the company is Buy. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #novartis #company #ag #job #market #bloomberg #pharmaceutical.